Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial

BACKGROUND Peri-operative management of anticoagulated patients with atrial fibrillation (AF) is challenging. To gain information on the peri-operative management of edoxaban, we compared outcomes in patients on warfarin or edoxaban enrolled in ENGAGE AF-TIMI 48 who underwent a surgery or invasive procedure. METHODS Data from patients undergoing their first surgery/procedure were analysed and results compared by anticoagulant (warfarin vs. higher- or lower-dose edoxaban regimen [HDER and LDER, respectively]). Patients were classified by procedural management: anticoagulant interrupted (last dose 4-10 days pre-procedure) or anticoagulant continued (last dose ≤ 3 days pre-procedure). Stroke/systemic embolism (SSE), major bleeding (MB), MB or clinically relevant non-MB (CRNMB) and death were assessed from 7 days pre- until 30 days post-procedure. The chi-square test was used to compare outcomes across treatment groups. RESULTS A total of 7,193 patients (34%) underwent surgery/procedure: 3,116 had anticoagulant interrupted, 4,077 had anticoagulant continued. Among patients on warfarin, HDER and LDER who had anticoagulant interrupted, rates of SSE were 0.6, 0.5 and 0.9% (p = 0.53), rates of MB were 1.0, 1.2 and 1.1% (p = 0.94) and rates of MB or CRNMB were 3.9, 4.2 and 3.6% (p = 0.78); among patients on warfarin, HDER and LDER who had anticoagulant continued, rates of SSE were 1.1, 0.7 and 0.9% (p = 0.51), rates of MB were 3.6, 2.6 and 2.4% (p = 0.13) and rates of MB or CRNMB were 8.5, 7.9 and 6.6% (p = 0.17). CONCLUSION In patients requiring surgery/procedure in ENGAGE AF-TIMI 48, peri-operative rates of SSE, MB and death were not significantly different in patients who received edoxaban or warfarin.

[1]  J. Douketis,et al.  Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide , 2008, Journal of thrombosis and haemostasis : JTH.

[2]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[3]  E. Antman,et al.  Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents , 2016, Circulation.

[4]  J. Douketis,et al.  The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[5]  Atul Verma,et al.  Pacemaker or defibrillator surgery without interruption of anticoagulation. , 2013, The New England journal of medicine.

[6]  D. Elmouchi,et al.  Safety of anticoagulation with uninterrupted warfarin vs. interrupted dabigatran in patients requiring an implantable cardiac device. , 2016, Cardiovascular diagnosis and therapy.

[7]  S. Connolly,et al.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. , 2016, The New England journal of medicine.

[8]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[9]  R. Giugliano,et al.  Practical management of anticoagulation in patients with atrial fibrillation. , 2015, Journal of the American College of Cardiology.

[10]  J. Douketis,et al.  Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. , 2009, Thrombosis research.

[11]  J. Douketis.  Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. , 2010, Current pharmaceutical design.

[12]  J. Douketis,et al.  Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy , 2012, Journal of thrombosis and haemostasis : JTH.

[13]  J. Douketis,et al.  Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines , 2015, Regional Anesthesia & Pain Medicine.

[14]  J. Douketis,et al.  Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[15]  D. Poli,et al.  The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use , 2016, Expert review of cardiovascular therapy.

[16]  H. Büller.  Edoxaban versus warfarin for venous thromboembolism. , 2014, The New England journal of medicine.

[17]  J. Mendell,et al.  The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults , 2015, Clinical Drug Investigation.

[18]  S. Yusuf,et al.  Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial , 2012, Circulation.

[19]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[20]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[21]  J. Douketis,et al.  Periprocedural anticoagulation practices in warfarin-treated patients who require elective angiography with or without percutaneous coronary intervention: a retrospective chart review. , 2010, Thrombosis research.

[22]  R. Giugliano,et al.  Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. , 2011, Future cardiology.

[23]  J. Douketis,et al.  The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale , 2017, Thrombosis and Haemostasis.

[24]  J. Douketis,et al.  Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery , 2016, Journal of thrombosis and haemostasis : JTH.

[25]  J. Douketis,et al.  To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment , 2016, Journal of thrombosis and haemostasis : JTH.

[26]  D. Xavier,et al.  Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. , 2014, Blood.

[27]  S. Yusuf,et al.  Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. , 2016, Thrombosis research.

[28]  G. Guyatt,et al.  Aspirin in patients undergoing noncardiac surgery. , 2014, The New England journal of medicine.

[29]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.